Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Intermitentní theta-burst stimulace ke zlepšení negativních symptomů a kognice u schizofrenie (ITBS-NKS-2024)

15. září 2026 aktualizováno: Schülke, Rasmus Dr., Hannover Medical School

Intermittierende Theta-Burst-Stimulation Zur Verbesserung Von Negativsymptomatik Und Kognition Bei Schizophrenie

The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.

The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:

Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.

Participants will:

  • Receive 10 sessions of iTBS over the course of 2 weeks
  • Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.

The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Lower Saxony
      • Hanover, Lower Saxony, Německo, 30625
        • Nábor
        • Hannover Medical School
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Rasmus Schülke, MD (Dr. med.)

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 65 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Diagnosis of schizophrenia (ICD-10: F20.-)
  • Age: 18-65 years
  • Ability to give informed consent
  • Signed informed consent form

Exclusion Criteria:

  • Any electronic implants
  • Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
  • Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
  • Claustrophobia
  • Epilepsy
  • History of traumatic brain injury within the last 3 months
  • History of stroke
  • Active central nervous system (CNS) infection
  • History of CNS infection within the last 3 months
  • Pregnancy
  • Current drug, medication, or alcohol abuse
  • Simultaneous participation in another clinical trial
  • Planned changes in psychopharmacological medication within the next 2 weeks
  • Severe physical illnesses that could endanger the patient, affect the examinations or make the MRI scanning cause additional burden

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: iTBS

Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Falešný srovnávač: Sham iTBS

Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in negative symptoms
Časové okno: From enrollment to the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to the end of iTBS treatment

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in negative symptoms at 4-week follow-up
Časové okno: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Speech-gesture rating task
Časové okno: From enrollment to the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task.

From enrollment to the end of iTBS treatment
Speech-gesture rating task at 4-week follow-up
Časové okno: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Eye-Tracking Task
Časové okno: From enrollment to the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task.

From enrollment to the end of iTBS treatment
Eye-Tracking Task at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
N-Back Test
Časové okno: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index).

From enrollment to the end of iTBS treatment
N-Back Test at 4-week follow-up
Časové okno: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index) 4 weeks after the end of iTBS treatment.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity
Časové okno: From enrollment to the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to 4 weeks after the end of iTBS treatment
FMRI: Task-related functional connectivity
Časové okno: From enrollment to the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to the end of iTBS treatment
FMRI: Task-related functional connectivity at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to 4 weeks after the end of iTBS treatment
Inflammatory cytokines
Časové okno: From enrollment to the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to the end of iTBS treatment
Inflammatory cytokines at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to 4 weeks after the end of iTBS treatment
Stimulation-associated perceptions
Časové okno: From the beginning of each iTBS stimulation to after the end of each iTBS stimulation

Stimulation-associated perceptions, measured using the TMS Adverse Events and Associated Sensations Questionnaire (TMSensQ, Section IV), after each iTBS session.

From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
Therapy dropout rate
Časové okno: From the beginning of iTBS treatment to the end of iTBS treatment

Therapy dropout rate (i.e. study termination).

From the beginning of iTBS treatment to the end of iTBS treatment
Serious Adverse Events (SAEs)
Časové okno: From the beginning of iTBS treatment to the end of iTBS treatment

Serious Adverse Events (SAEs), measured using TMSensQ (Section V).

From the beginning of iTBS treatment to the end of iTBS treatment
Self-reported depression: BDI-II
Časové okno: From enrollment to the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to the end of iTBS-treatment
Self-reported depression at 4-week follow-up: BDI-II
Časové okno: From enrollment to 4 weeks after the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Self-rated gesture perception and production: BAG
Časové okno: From enrollment to the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to the end of iTBS-treatment
Self-rated gesture perception and production at 4-week follow-up: BAG
Časové okno: From enrollment to 4 weeks after the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Epigenetic changes of neurotrophic and immunological factors
Časové okno: From enrollment to the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to the end of iTBS treatment
Epigenetic changes of neurotrophic and immunological factors at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to 4 weeks after the end of iTBS treatment
Concentrations of markers of neuronal damage
Časové okno: From enrollment to the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to the end of iTBS treatment
Concentrations of markers of neuronal damage at 4-week follow-up
Časové okno: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to 4 weeks after the end of iTBS treatment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Rasmus Schülke, MD (Dr. med.), Hannover Medical School

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

8. dubna 2025

Primární dokončení (Odhadovaný)

31. prosince 2026

Dokončení studie (Odhadovaný)

31. prosince 2026

Termíny zápisu do studia

První předloženo

14. prosince 2024

První předloženo, které splnilo kritéria kontroly kvality

14. prosince 2024

První zveřejněno (Aktuální)

18. prosince 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

15. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 11473_BO_S_2024

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Popis plánu IPD

Whether IPD may be shared has not yet been decided. IPD might not be shared due to data protection laws.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .